Theriva Biologics Inc TOVX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TOVX is a good fit for your portfolio.
News
-
Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma
-
Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting
-
Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting
-
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results
-
Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results
-
Theriva™ Biologics to Participate in the BIO-Europe Spring Conference
-
Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
-
Theriva Gets Orphan Drug Designation for VCN-01 to Treat Pancreatic Cancer
Trading Information
- Previous Close Price
- $0.42
- Day Range
- $0.41–0.43
- 52-Week Range
- $0.20–1.20
- Bid/Ask
- $0.42 / $0.44
- Market Cap
- $7.05 Mil
- Volume/Avg
- 537,536 / 118,838
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 21
- Website
- https://www.therivabio.com
Valuation
|
Metric
|
TOVX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.20 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TOVX
|
|---|---|
Quick Ratio | 3.73 |
Current Ratio | 4.07 |
Interest Coverage | — |
Quick Ratio
TOVX
Profitability
|
Metric
|
TOVX
|
|---|---|
Return on Assets (Normalized) | −27.71% |
Return on Equity (Normalized) | −40.04% |
Return on Invested Capital (Normalized) | −38.74% |
Return on Assets
TOVX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rndcnxpgy | Xvyn | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ybcpjvmr | Wnprbx | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zbqxjdyjl | Qvqqtj | $98.8 Bil | |
MRNA
| Moderna Inc | Ggrfbvsgk | Nylp | $38.8 Bil | |
ARGX
| argenx SE ADR | Ymcpzvxj | Nyb | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Jphlyhr | Mkrd | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rshhrvpmq | Cnhfl | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fxkrlnjyl | Hjmjt | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ypzcsjqdb | Wgqbks | $12.4 Bil | |
INCY
| Incyte Corp | Gfngytzc | Ktfhbs | $11.9 Bil |